These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 17363562

  • 1. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM.
    Cancer Res; 2007 Mar 15; 67(6):2448-55. PubMed ID: 17363562
    [Abstract] [Full Text] [Related]

  • 2. Suppression of centrosome amplification after DNA damage depends on p27 accumulation.
    Sugihara E, Kanai M, Saito S, Nitta T, Toyoshima H, Nakayama K, Nakayama KI, Fukasawa K, Schwab M, Saya H, Miwa M.
    Cancer Res; 2006 Apr 15; 66(8):4020-9. PubMed ID: 16618721
    [Abstract] [Full Text] [Related]

  • 3. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD, Kees UR, Tweddle DA, Lunec J.
    Oncogene; 2012 Feb 09; 31(6):752-63. PubMed ID: 21725357
    [Abstract] [Full Text] [Related]

  • 4. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
    Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.
    Neoplasia; 2009 Aug 09; 11(8):753-62. PubMed ID: 19649205
    [Abstract] [Full Text] [Related]

  • 5. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
    He J, Gu L, Zhang H, Zhou M.
    Cell Cycle; 2011 Sep 01; 10(17):2994-3002. PubMed ID: 21862876
    [Abstract] [Full Text] [Related]

  • 6. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M, Veschi V, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, Dominici C, McDowell HP, Rinaldi C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Soddu S, Giannini G.
    Mol Cancer Res; 2011 Jan 01; 9(1):67-77. PubMed ID: 21173028
    [Abstract] [Full Text] [Related]

  • 7. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis.
    Slack A, Shohet JM.
    Cell Cycle; 2005 Jul 01; 4(7):857-60. PubMed ID: 15917661
    [Abstract] [Full Text] [Related]

  • 8. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
    Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, Lunec J, Tweddle DA.
    Cell Cycle; 2011 Nov 01; 10(21):3778-87. PubMed ID: 22052359
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
    Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM.
    Proc Natl Acad Sci U S A; 2005 Jan 18; 102(3):731-6. PubMed ID: 15644444
    [Abstract] [Full Text] [Related]

  • 11. Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells.
    Sugihara E, Kanai M, Matsui A, Onodera M, Schwab M, Miwa M.
    Oncogene; 2004 Jan 29; 23(4):1005-9. PubMed ID: 14647433
    [Abstract] [Full Text] [Related]

  • 12. p53 is a direct transcriptional target of MYCN in neuroblastoma.
    Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.
    Cancer Res; 2010 Feb 15; 70(4):1377-88. PubMed ID: 20145147
    [Abstract] [Full Text] [Related]

  • 13. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
    Gu L, Zhang H, He J, Li J, Huang M, Zhou M.
    Oncogene; 2012 Mar 15; 31(11):1342-53. PubMed ID: 21822304
    [Abstract] [Full Text] [Related]

  • 14. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
    Ramaiah MJ, Pushpavalli SN, Lavanya A, Bhadra K, Haritha V, Patel N, Tamboli JR, Kamal A, Bhadra U, Pal-Bhadra M.
    Bioorg Med Chem Lett; 2013 Oct 15; 23(20):5699-706. PubMed ID: 23992861
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
    Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, Beisel C, Gogolin S, Fischer M, Henrich KO, Ehemann V, Gillespie P, Schwab M, Westermann F.
    Cancer Res; 2010 May 01; 70(9):3791-802. PubMed ID: 20424123
    [Abstract] [Full Text] [Related]

  • 16. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, Tang XX.
    Int J Oncol; 2011 Jan 01; 38(1):105-12. PubMed ID: 21109931
    [Abstract] [Full Text] [Related]

  • 17. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F.
    Cell Cycle; 2013 Apr 01; 12(7):1091-104. PubMed ID: 23462184
    [Abstract] [Full Text] [Related]

  • 18. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
    Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, Douc-Rasy S, Cappellen D.
    Nucleic Acids Res; 2008 Aug 01; 36(13):4222-32. PubMed ID: 18583365
    [Abstract] [Full Text] [Related]

  • 19. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
    Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J.
    Am J Pathol; 2001 Jun 01; 158(6):2067-77. PubMed ID: 11395384
    [Abstract] [Full Text] [Related]

  • 20. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
    Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.
    Cancer Res; 2015 Dec 01; 75(23):5143-54. PubMed ID: 26471359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.